PharmaVentures http://www.pharmatelevision.com PharmaVentures Business Review is a new cutting edge television business show that provides viewers with effortless access to essential industry intelligence. PharmaVentures Business Review PharmaVentures Business Review will keep you informed with our insightful coverage of major transactions and pharmaceutical industry trends, as well as giving you exclusive access to topical interviews with senior executives and independent expert opinions, including opinions from the financial sector. Fintan Walton interviews key industry figures in the biotech and pharmaceutical industry. en PharmaVentures Ltd 2006 PharmaVentures Ltd enquiries@pharmaventures.com http://www.pharmatelevision.com/images/core/logo.gif http://www.pharmatelevision.com Business no PharmaVentures Ltd This insightful conversation features Graeme Martin, CEO of Takeda Research Investment (TRI)—the corporate venture arm of Takeda Pharmaceutical. Interview with Graeme Martin This insightful conversation features Graeme Martin, CEO of Takeda Research Investment (TRI)—the corporate venture arm of Takeda Pharmaceutical, the largest pharma company in Japan and among the largest in the world. Dr. Martin shares TRI’s plans to invest US$100 million seed money in a variety of early-stage innovative ventures, to help expand Takeda’s research horizons outside Japan. With a plan to invest in 4-5 new efforts a year, TRI hopes to eventually manage a steady state investment of about 20 companies that will include both minority investments and active, collaborative partnerships designed to create synergies with Takeda’s considerable R&D resources. http://www.pharmatelevision.com/media/pvbr_f2f73_graememartin.m4v Tue, 06 May 2008 00:00:00 -0000 Business no 9:09 Takeda Investment, Graeme Martin PharmaVentures Ltd In this exclusive interview Fintan Walton talks to Richard Eccles, Partner at law firm Bird & Bird. Interview with Richard Eccles In this interview for PTV, Fintan Walton talks to Richard Eccles, Partner at the international law firm Bird & Bird, on the contents of the report entitled ‘Competition Law and Intellectual Property Strategy in the Pharmaceuticals Sector’, written by Richard and his colleague Gerry Kamstra, of Bird & Bird. This major new report is a co-publication between PharmaVentures and Bird & Bird. In the interview Richard explains the importance of understanding competition law, and how these operate across the EU. Pricing and regulatory issues are discussed in-depth, and Richard comments on the changing levels of complexity of regulatory laws. He also gives a summary on generic companies’ stance within competition law. Richard illustrates these points using specific cases involving GlaxoSmithKline and AstraZeneca. http://www.pharmatelevision.com/media/pvbr_f2f77_richardeccles.m4v Tue, 29 Apr 2008 00:00:00 -0000 Business no 17:39 competition law, Bird & Bird, Richard Eccles PharmaVentures Ltd In this new interview, Fintan Walton talks to Richard de Souza, CEO of Archimedes Pharma. Interview with Richard de Souza In this new interview, Fintan Walton talks to Richard de Souza, CEO of Archimedes Pharma. Richard describes how Archimedes' strategy has evolved over the 18 months since his last appearance on PharmaTelevision. He discusses the strategic acquisitions the company has undertaken to establish itself, and summarises the company's presence within the major European markets. An interesting conversation develops about the challenges facing speciality pharma in Europe, followed by Richard's outline of Archimedes' current plans for commercialising their products in the US. The two conclude the interview with a discussion of the de-risking of Archimedes' development strategy, how this was applied to its lead product, NasalFent®, and the company's plans for the coming 12 months. http://www.pharmatelevision.com/media/pvbr_f2f72_richarddesouza.m4v Tue, 22 Apr 2008 12:00:00 -0000 Business no 19:16 Archimedes Pharma, de souza, speciality, pharma PharmaVentures Ltd In this exclusive interview, Fintan Walton talks to Onno van de Stolpe, CEO of Galapagos. Interview with Onno van de Stolpe In this exclusive interview, Fintan Walton talks to Onno van de Stolpe, CEO of Galapagos. Onno discusses the expansion of Galapagos over the last few years, especially in terms of the company’s pipeline. Much of this progress can be attributed to alliances with major pharmas, including GlaxoSmithKline and Eli Lilly. Onno talks about the contribution of BioFocus DPI, Galapagos’ fee-for-service division, to the growth of the company. Galapagos’ deal with Janssen Pharmaceutica is also discussed and Onno dissects the structure of the deal. The acquisition of ProSkelia from ProStrakan is covered as well. Onno explains the reasons behind Galapagos’ decision to delist from AIM, and outlines the recent operation of the company’s Level 1 American Depositary Receipt (ADR) facility in the US. He discusses Galapagos’ gradual shift of its business model, and concludes the interview with his view on the possibility of divesting Biofocus DPI in the coming years. http://www.pharmatelevision.com/media/pvbr_f2f71_onnovandestolpe.m4v Tue, 15 Apr 2008 00:00:00 -0000 Business no 17:28 Galapagos, alliance, deal, Biofocus DPI, Proskelia, AIM, Level 1 American Depositary Receipt PharmaVentures Ltd In this exclusive interview, Fintan Walton talks to Bryan Morton, Founder and CEO of EUSA Pharma. Interview with Bryan Morton In this exclusive interview, Fintan Walton talks to Bryan Morton, Founder and CEO of EUSA Pharma. Bryan begins by discussing the establishment of EUSA Pharma, and how its formation was motivated by the successful acquisition of Zeneus Pharma (also founded by Bryan), by Cephalon in 2005. Bryan talks about the three speciality pharma models employed by EUSA, the similiarities and differences between the US and Europe speciality pharma and the reason for basing EUSA in the US. He also talks about EUSA’s strategy in Europe versus the strategies of the more traditional, private European mid-sized companies. Bryan speculates on the future of speciality pharma companies, and of EUSA in particular. The interview ends with a discussion of EUSA’s pending acquisition of US company Cytogen, and EUSA’s strategy with regard to further acquisitions. http://www.pharmatelevision.com/media/pvbr_f2f70_bryanmorton.m4v Tue, 08 Apr 2008 12:00:00 -0000 Business no 19:26 EUSA Pharma, Bryan Morton,specialty, speciality, Zeneus Pharma, Cytogen PharmaVentures Ltd Fintan Walton talks to Richard Barker, Director General of the ABPI. Interview with Richard Barker In this exclusive interview, Fintan Walton talks to Richard Barker, Director General of the Association of the British Pharmaceutical Industry (ABPI). Richard describes the role of the ABPI within the UK pharma/biotech industry, and discusses the key messages that the ABPI is currently involved in passing to the Government and patient groups. He outlines the increase in global competition, its effect on the industry within the UK, and the current affordability issues to UK patients in accessing life-saving drugs. Richard stresses the importance of amicable collaborations between drug development, regulatory authorities and government in ensuring the availability of innovative medicines. The interview is concluded with his outlook on the potential of the industry, and the major issues that must be tackled. http://www.pharmatelevision.com/video/521/288/pvbr_f2f69_richardbarker.m4v Tue, 01 Apr 2008 00:00:00 -0000 Business no 16:36 ABPI, Richard Barker, UK, Britain, Association of the British Pharmaceutical Industry PharmaVentures Ltd In this exclusive interview, Fintan Walton talks to Ben Cons, Vice President of NovaQuest. Interview with Ben Cons In this exclusive interview, Fintan Walton talks to Ben Cons, Vice President of NovaQuest, about NovaQuest’s functions and operations, and how these differ from those of its parent company, Quintiles Transnational. Ben talks about the financial commitment NovaQuest has made to its partnerships and how this is split between its biotech and large pharma clients. He outlines the two principle ways in which NovaQuest operates with companies, and how it shares some of the risks and returns. Ben discusses the current changes in the industry, the drivers for these changes, and how they affect NovaQuest’s business. He highlights some examples of partnerships that show how the company is adapting to these changes – in particular he discusses its alliances with Eli Lilly and Solvay Pharmaceuticals. Ben talks about how NovaQuest manages the risk within its alliance portfolio and the company’s approach to its equity contributions in life sciences companies. Finally, he gives his opinion on the progress of the industry from NovaQuest’s viewpoint, and discusses how the company will grow in relation to Quintiles. http://www.pharmatelevision.com/video/521/288/pvbr_f2f68_bencons.m4v Tue, 25 Mar 2008 00:00:00 -0000 Business no 16:56 NovaQuest, partnership, alliance, ben cons, Quintiles PharmaVentures Ltd In this exclusive interview, Fintan Walton talks to Nick Lench, CEO of London Genetics. Interview with Nick Lench In this exclusive interview, Fintan Walton talks to Professor Nick Lench, CEO of London Genetics, about the company’s vision to facilitate access for biotech and pharmaceutical companies to the wealth of genetic information and expertise at a number of London’s leading academic institutes. Nick discusses the company’s overall strategy, the services that it is providing and the benefits that a single point of access brings to London’s genetics community. http://www.pharmatelevision.com/video/521/288/pvbr_f2f47_lench.m4v Tue, 18 Mar 2008 00:00:00 -0000 Business no 11:16 london, academic,university, Nick Lench, genetics PharmaVentures Ltd In this exclusive interview, Fintan Walton talks to Lise Kagenow, Managing Director of Novarix. Interview with Lise Kagenow Fintan Walton talks to Lise Kagenow, Managing Director of Novarix. Lise explains how her early career prompted her to become an inventor and entrepreneur and set up Novarix as a company. She goes on to talk in more detail about her first invention Stabi-Line™: a patented medical device to stabilise iv infusion lines. They discuss the steps involved in bringing an invention to market - from developing the idea and raising finance, to licensing the product for commercialisation. The interview concludes with Lise talking about the ‘Innovation Advisory Service’ scheme which she established to provide advice to budding inventors. http://www.pharmatelevision.com/video/521/288/pvbr_f2f49_kagenow.mov Tue, 11 Mar 2008 00:00:00 -0000 Business no 15:34 Novarix, Lise Kagenow, Stabi-Line, IV infusion PharmaVentures Ltd In this exclusive interview, Fintan Walton talks to Safi Bahcall, President and CEO of Synta Pharmaceuticals. Interview with Safi Bahcall In this exclusive interview, Fintan Walton talks to Safi Bahcall, President and CEO of Synta Pharmaceuticals. They begin by discussing Synta’s origins, and how the company was established through the research of Harvard and MIT scientists. Safi talks about Synta’s lead anticancer product and explains its mechanism of action, as well as reviewing the current state of the company’s pipeline. He expands upon the terms of Synta’s major agreement with GlaxoSmithKline and the interview concludes with a discussion of Synta’s growth strategy. http://www.pharmatelevision.com/video/521/288/pvbr_f2f64_safibahcall.mov Tue, 04 Mar 2008 00:00:00 -0000 Business no 12:22 Synta, Safi Bahcall, Harvard, MIT, anticancer, GlaxoSmithKline PharmaVentures Ltd In this exclusive interview, Fintan Walton and Matt Gardner, President and CEO of BayBio, look back on 2007 Interview with Matthew Gardner In this exclusive interview - filmed at the JP Morgan conference in San Francisco - Fintan Walton and Matt Gardner, President and CEO of BayBio, look back on 2007, beginning with Matt Gardner’s assessment of the biotech industry for the past year. Matt mentions the benchmarks that are used to quantify the state of the industry - which includes the status of the product pipelines of biotech companies. The interview moves on to discuss the key issues facing the biotech industry in light of the run-up to the 2008 US presidential elections. Matt talks about the major issues that one needs to be aware of with regard to the individual presidential candidates. These include their views on healthcare and on patent reform, and Matt says why he thinks the outcome of the patent reform debate is the most sensitive issue. The interview progresses towards examining the decline in venture funding of early-stage and seed companies - and how this may result in a future company ‘gap’. Personalised medicine, and its potential for eventually lowering the cost of healthcare is discussed. The interview concludes with Matt’s optimistic outlook for the industry. http://www.pharmatelevision.com/media/pvbr_f2f63_mattgardner.m4v Tue, 26 Feb 2008 00:00:00 -0000 Business no 13:39 BayBio, Matthew Gardner, JP Morgan, pharma, biotech, personalised medicine, deals, alliances PharmaVentures Ltd Fintan Walton talks to Alice Huxley, CEO of the Swiss biopharmaceutical company Speedel Interview Over a year on from their last discussion, Fintan Walton talks to Alice Huxley, CEO of the Swiss biopharmaceutical company Speedel. They look back at the company’s successes during 2007, in particular the launch of its renin inhibitor Tekturna® (aliskiren, SPP100) in the US and Europe. This is not only a first-in-class product, but the first of Speedel’s compounds to reach the market. The company’s plans to develop Tekturna further and to expand within the renin inhibitor field through its other drug candidates are also discussed. Alice goes on to offer an insight into the company’s strategy going forward in terms of whether it plans to in-license products or grow organically, and also talks about what 2008 may hold for Speedel. http://www.pharmatelevision.com/media/pvbr_f2f67_alicehuxley.m4v Tue, 19 Feb 2008 00:00:00 -0000 Business no 14:46 Speedel, Alice Huxley, deals, alliances, pharma, biotech, renin inhibitor, tekturna PharmaVentures Ltd Interview with Christian Itin Interview with Christian Itin In this interview, Fintan Walton talks to Christian Itin, President and CEO of antibody technology company Micromet. Christian talks about how the company was set up in Munich to address one of the gaps in cancer therapy: treatment of the stage of the disease known as micrometastases. He goes on to describe how the decision to launch an IPO in Europe in 2005 was overturned in favour of entering into a reverse merger agreement with CancerVax, through which Micromet was able to forward integrate into the US and gain a listing on Nasdaq. Christian then discusses in some detail Micromet’s antibody technology and the company’s alliances, including the one with MedImmune and the effect that the ensuing merger with AstraZeneca had on the partnership. http://www.pharmatelevision.com/media/pvbr_f2f68_christianitin.m4v Tue, 12 Feb 2008 00:00:00 -0000 Business no 16:38 micromet, ipo, reverse merger, pharma, biotech, antibody, bite, medimmune, micrometastases, christian itin PharmaVentures Ltd Interview with Edwin Moses Interview with Edwin Moses Fintan Walton talks to Edwin Moses, CEO of Ablynx, about the success that the company has enjoyed since its inception, and his plans for it going forward. Edwin talks about the importance of location in relation to the financing environment, and the difference in the ease of raising cash through an IPO depending upon your location. He also expands upon Ablynx’s commercial strategy in terms of partnering with big pharma, acquiring other technologies, targets and products, and Ablynx’s goal of becoming a fully integrated, independent pharmaceutical company in its own right. http://www.pharmatelevision.com/media/pvbr_f2f66_edwinmoses.m4v Tue, 05 Feb 2008 00:00:00 -0000 Business no 15:14 Ablynx, Edwin Moses, pharma, biotech, financing, deals, alliances, IPO PharmaVentures Ltd Interview with Anna Lavelle Interview with Anna Lavelle In this exclusive interview, Fintan Walton talks to Anna Lavelle, CEO of AusBiotech, about how the organisation performs its role as the interface between commerce, research scientists and the federal and state government agencies in Australia. Anna also outlines the progress the Australian biotechnology industry has made and discusses how AusBiotech plans to maintain that trend. The emergence of Australia as a significant player in the industry was reflected in the success of AusBiotech 2007 and Anna goes on to talk about the plans to further improve next year’s conference. http://www.pharmatelevision.com/media/pvbr_f2f38_annalavelle.m4v Mon, 04 Feb 2008 00:00:00 -0000 Business no 17:04 Anna Lavelle, AusBiotech, biotech, pharma, conferences, investment, deals, alliances PharmaVentures Ltd Interview with Peter Devine Interview with Peter Devine In this exclusive interview, Fintan Walton talks to Peter Devine, CEO of Uniseed Management, about the origins of the business. He discusses how it began as a US$20 M fund, founded by the Universities of Queensland and Melbourne, to bridge the gap between the Universities’ research and the financial market. He describes how the company has evolved through investment commitment from Westscheme (Western Australia's largest non-government superannuation fund) and the University of New South Wales, along with further investment from the founding Universities. Dr Devine also talks about the criteria used by the company when considering an investment opportunity, as well as discussing a few specific examples of investments made. http://www.pharmatelevision.com/media/pvbr_f2f61_peterdevine.m4v Sun, 03 Feb 2008 00:00:00 -0000 Business no 18:48 pharma, biotech, Peter Devine, Uniseed Management, Westscheme, investment PharmaVentures Ltd Interview with Pete Smith Interview with Pete Smith In this exclusive interview, Fintan Walton talks to Pete Smith, CEO of Alchemia, about the origins of the company in carbohydrate chemistry, and how these origins led to a unique position in the manufacture of fondaparinux through an agreement with Dr Reddy’s. Pete also outlines the hyaluronic acid technology gained through the acquisition of Meditech, and how the company is using this in oncology. Alchemia’s strategic positioning as a drug discovery company that blends rational drug design with random high throughput screening is also discussed. http://www.pharmatelevision.com/media/pvbr_f2f60_petesmith.m4v Sun, 03 Feb 2008 00:00:00 -0000 Business no 7:45 carbohydrate chemistry, pharma, biotech, Alchemia, fondaparinux, hyaluronic acid, drug discovery PharmaVentures Ltd Interview with Steven Mercer Interview with Steven Mercer In this interview, Fintan Walton talks to Steven Mercer, CEO of Tissue Therapies. They begin with a discussion of the origin of the company, which was established to commercialise research developed at the Queensland University of Technology (QUT). Steven explains in detail the company’s platform technology, VitroGro®, its application in therapeutics and tissue culture media, and its versatility. The discussion then covers the worldwide sales and distribution agreement that Tissue Therapies made with Invitrogen in 2007, including the revenues that the company is entitled to from Invitrogen. The patent protection that applies to VitroGro is outlined, in particular the broadness of the cover of the family of patents. Steven then talks about a recombinant protein based on VitroGro technology being developed by the company for diabetic venous and pressure ulcers. The interview concludes with his ideas on VitroGro’s commercial potential. http://www.pharmatelevision.com/media/pvbr_f2f58_stevenmercer.m4v Sun, 03 Feb 2008 00:00:00 -0000 Business no 14:08 Steven Mercer, Tissue Therapies, pharma, biotech, platform technology, Vitrogro, deal, alliance PharmaVentures Ltd Interview with Dave Pritchard Interview with Dave Pritchard In this exclusive interview, Fintan Walton talks to Dave Pritchard, CEO of KaloBios Pharmaceuticals, about this antibody-based company, its platform technology and its research programmes. Dave discusses KaloBios’ financing through funding rounds, and its 2007 licensing deal with Novartis. He talks about KaloBios’ plans to raise more money through further partnering, and how the company has also been recently approached by strategic investors, leading to the possibility of an unusual corporate round of funding. Dave also touches on similarities between KaloBios and his last antibody company, Rinat Neuroscience, which was acquired by Pfizer for US$500 M, and mentions the possibility of KaloBios being similarly acquired. http://www.pharmatelevision.com/media/pvbr_f2f65_davepritchard.m4v Tue, 29 Jan 2008 00:00:00 -0000 Business no 13:27 KaloBios, Dave Pritchard, strategy PharmaVentures Ltd Interview with Barbara Yanni Interview with Barbara Yanni In this exclusive interview, live from San Francisco, Fintan Walton talks to Barbara Yanni, Vice President and Chief Licensing Officer at Merck & Co. Although Merck is often perceived as being internally focused and has, historically at least, not been known for doing deals, the company is now fully committed to partnering. Its pipeline is strong, with seven compounds in Phase III, of which three were in-licensed during 2007. Barbara and Fintan discuss the methods that Merck uses to source new licensing opportunities, how it competes with other big pharmas and how its alliances are managed. They also look ahead to what 2008 is likely to bring to the pharma/biotech industry. http://www.pharmatelevision.com/media/pvbr_f2f62_barbarayanni.m4v Tue, 22 Jan 2008 00:00:00 -0000 Business no 20:31 Merck, alliance management, deals, biotech, pharma, Barbara Yanni, alliance PharmaVentures Ltd Interview with Peter Mountford Interview with Peter Mountford In this exclusive interview, Fintan Walton talks to Peter Mountford, formerly CEO of Stem Cell Sciences, about the current state of stem cell technologies and their potential healthcare and research applications. The company is now at the ‘end of the beginning stage’, and has the capability to mass produce stem cells, with which it hopes to provide a range of products and services. The impact of emerging stem cell technologies on ethical concerns is discussed, as well as the likely commercialisation process of the technology. Peter also outlines the challenge in gaining funding for stem cell research, particularly from venture capital firms. http://www.pharmatelevision.com/media/pvbr_f2f59_petermountford.m4v Mon, 14 Jan 2008 00:00:00 -0000 Business no 20:42 Peter Mountford, Stem Cell Sciences, stem cells, biotech, pharma, funding, venture capital PharmaVentures Ltd Interview with Stewart Washer Interview with Stewart Washer In this exclusive interview, Fintan Walton talks to Dr Stewart Washer, CEO of Phylogica, about the company’s research using its peptide-based drug discovery technology platform. He discusses the challenges faced by an Australian preclinical-stage biotech in obtaining funding, and how Phylogica’s business model aims to do this through both equity financing and deals with other companies. Dr Washer talks about Phylogica’s current collaborations with Johnson & Johnson Research and with Opsona, and how he believes that the interest of bigger pharmas in Phylogica will grow once the company’s compounds are in Phase I/IIa clinical development. Finally, he discusses how Phylogica’s strategy also includes gaining complementary technologies – both disease targets in the area of inflammation and drug delivery technologies – through acquisitions and partnerships. http://www.pharmatelevision.com/media/pvbr_f2f57_stewartwasher.m4v Tue, 08 Jan 2008 00:00:00 -0000 Business no 18:07 Phylogica, Australia, preclinical, biotech, funding, drug delivery, pharma PharmaVentures Ltd Interview with Stephen Patillo and David Boncosky Interview with Stephen Patillo and David Boncosky In this interview, which took place in Brisbane at AusBiotech 2007, Fintan Walton talks to Stephen Patillo and David Boncosky who are both Directors at Indiana Economic Development Corporation (IEDC). Stephen and David talk about how IEDC helps companies to establish themselves in the US state of Indiana, and how Stephen runs the overseas office for Australia and New Zealand. They discuss the types of companies typically assisted and highlight Portland Orthopaedics as a good example of one of their clients. The benefits of having operations in Indiana are discussed, including the region’s ‘vibrant biosciences ecosystem’. http://www.pharmatelevision.com/media/pvbr_f2f55_stephenpatillo.m4v Tue, 01 Jan 2008 00:00:00 -0000 Business no 15:15 indiana economic development corporation, Indiana, centre of excellence, bioscience, portland orthopaedics PharmaVentures Ltd Interview with Clive Goddard Interview with Clive Goddard Fintan Walton talks to Clive Goddard, PharmaVentures’ resident cartoonist for PharmaDeals. During the interview, Clive talks about his motivation for becoming a cartoonist and how he has always enjoyed creating his own ideas. They talk about how the production of the PharmaDeals cartoons is truly a team effort and how the pharmaceutical industry, perhaps surprisingly, is good cartoon fodder. With over 60 industry cartoons in print, Clive has provided amusement to PharmaVentures’ customers for the past 4 years. http://www.pharmatelevision.com/media/pvbr_f2f54_goddard.m4v Fri, 21 Dec 2007 00:00:00 -0000 Business no 9:44 clive goddard, cartoon, private eye PharmaVentures Ltd Interview with John Clerici Interview with John Clerici Fintan Walton talks to John Clerici, a partner in McKenna Long & Aldridge, whose practice is in Public Health Preparedness. This interview covers the funding available from the US Government to commercial companies for the development of technologies to protect public health (such as the prevention of flu pandemics and other viral outbreaks) and bioterrorism. Since 9/11, the US Government has increased its spending on these areas and will partner with companies (US or non-US) to accelerate the development of relevant products. John Clerici also covers what commercial organisations should be aware of in entering into these partnerships, and what they should be aiming for. Executed correctly, partnerships with the US Government can result in a product that benefits both public health and the fight against bioterrorism, and the pharmaceutical or biotech company concerned. http://www.pharmatelevision.com/media/pvbr_f2f54_johnclerici.m4v Tue, 18 Dec 2007 00:00:00 -0000 Business no 12:13 John Clerici, public health preparedness, funding, government partnerships PharmaVentures Ltd Interview with Alison Coutts Interview with Alison Coutts In this exclusive interview, Fintan Walton talks to Alison Coutts, Executive Director at eG Capital in Sydney, Australia. Alison reviews some of the major changes she has observed in the biotech and pharmaceutical industry in Australia over the last 12 months, reflecting on the progress that many companies have made and the general maturation of the industry as a whole. She discusses the increasing interest which Australia’s biotech sector is receiving from international pharmaceutical companies and comments on the nature of the relationship which these major players are intent on seeking. Alison also provides a look ahead to 2008 and what it might hold for Australia’s many biotech companies. http://www.pharmatelevision.com/media/pvbr_f2f53_alisoncoutts.m4v Fri, 07 Dec 2007 00:00:00 -0000 Business no 16:09 Alison Coutts, eg capital, australia, biotech PharmaVentures Ltd Interview with Simon Moroney Interview with Simon Moroney Fintan Walton talks to Dr Simon Moroney, Co-Founder and CEO of MorphoSys, in this exclusive TV interview following the company’s US$1 B deal with Novartis on 2 December 2007. The long-term collaboration agreement is focused on MorphoSys’ HuCAL human antibody technology, and has been hailed as a transforming deal for MorphoSys. Dr Moroney talks about the structure of the agreement and how it affects the company’s existing partnerships. He goes on to discuss MorphoSys’ investment in its own pipeline, and how he sees this advancing the company in the future. http://www.pharmatelevision.com/video/521/288/pvbr_f2f56_moroney.m4v Fri, 07 Dec 2007 00:00:00 -0000 Business no 6:21 simon moroney, morphosys, Novartis, antibody, collaboration, HuCAL PharmaVentures Ltd Interview with Marcus O’Neill Interview with Marcus O’Neill In this exclusive interview, Fintan Walton talks to Marcus O’Neill, VP Life Science Finance at GE Healthcare Financial Services. The topic of this week’s discussion is debt financing, or ‘venture debt’, as it is also known. Marcus talks through the structure of this type of lending, particularly in the case of early-stage companies. He emphasises the need for companies to have backing from good quality venture capital funding, long-term future value and assigned IP, and draws on Astex Therapeutics and Arrow Therapeutics as examples of high-profile recipients of debt financing. http://www.pharmatelevision.com/video/521/288/pvbr_f2f46_oneill.m4v Tue, 04 Dec 2007 00:00:00 -0000 Business no 15:08 debt financing, venture debt, GE Healthcare Finance, Marcus O'Neill, IP, credit crunch, VC PharmaVentures Ltd Interview with Dr Susan Pond Interview with Dr Susan Pond In this exclusive interview, Fintan Walton talks to Dr Susan Pond, Managing Director of Johnson & Johnson Research in Australia, about the company’s position in the J&J organisation, and how J&J is one of the few multinational companies that has a bona fide biotechnology discovery presence in Australia. She discusses how the company centres on RNA and DNA research, but also looks for Australian technology that could be of value to J&J globally. Dr Pond also describes the importance of the company’s interaction with local academic organisations, through both collaboration agreements and the joint supervision of PhD students. http://www.pharmatelevision.com/video/521/288/pvbr_f2f52_susanpond.m4v Tue, 27 Nov 2007 00:00:00 -0000 Business no 8:15 PharmaVentures Ltd Interview with Graham Brazier Interview with Graham Brazier In this exclusive interview, Fintan Walton talks to Graham Brazier, Vice President and Head of Business Development at Bristol-Myers Squibb (BMS), about the world of big pharma business development and the process of in-licensing. Because the interview took place at the AusBiotech 2007 conference, particular reference is made to the importance and challenges of making deals in Australia. Graham also details the rationale between BMS’ collaborations with fellow big pharma companies AstraZeneca and Pfizer, as well as discussing BMS’ acquisition of Adnexus. http://www.pharmatelevision.com/video/521/288/pvbr_f2f48_brazier.m4v Tue, 20 Nov 2007 00:00:00 -0000 Business no 21:42 Brazier, Business Development, Australia, Bristol-Myers Squibb, BMS PharmaVentures Ltd Month in Review Learn about the key deals in October 2007 Learn about the key deals in October 2007 and what they have meant for the companies involved. Featured deals include those between GlaxoSmithKline and Synta Pharmaceuticals, Aspreva and Galenica, and others. http://www.pharmatelevision.com/video/521/288/pvbr_mir01.m4v Wed, 14 Nov 2007 00:00:00 -0000 Business no 15:09 alliance, acquisition, licensing, rights, upfront, headline PharmaVentures Ltd Interview with Marc Fredj and Richard Wallis Interview with Marc Fredj and Richard Wallis Fintan Walton talks live from Geneva to Marc Fredj and Richard Wallis, Associates in the Life Sciences Group at Simmons & Simmons. Specifically, the interview gives a legal perspective on licensing and M&As within the life sciences industry. The interview commences with a discussion on a recent Simmons and Simmons report which focuses on trends in the licensing deals and acquisitions that are taking place in the industry. Among the issues discussed is the increase in the number of earlier stage licensing deals. Marc talks about how the bargaining power in structuring a deal is shifting more towards the smaller biotechs, and the reasons why this may be so. The participants discuss how the geography of a licensing deal will, increasingly, incorporate the entire world, rather than a few countries. They also deliberate on the increase in the number of acquisitions involving biotechs, which is a recent trend, and consider the challenges that may arise in such transactions – challenges of which biotechs need to be aware should they partake in an acquisition. The differences between the due diligence carried out for a licensing deal compared with the process for an acquisition deal are discussed, as well as reasons why acquisitions are the more favoured deal type for the moment. Litigation issues in the industry are also covered, followed by a discussion on whether deals are becoming more complex – in terms of both financing and IP. http://www.pharmatelevision.com/video/521/288/pvbr_f2f44_simmons.m4v Tue, 06 Nov 2007 00:00:00 -0000 Business no 19:42 Simmons and Simmons, legal, licensing, acquisition, biotech, pharma PharmaVentures Ltd Interview with Khatereh Ahmadi Interview with Khatereh Ahmadi In this exclusive interview, Fintan Walton talks to Khatereh Ahmadi, Business Development Director at the UK biotech Piramed Pharma, about the company’s formation following a collaboration between Yamanouchi Pharmaceutical (now Astellas Pharma), Cancer Research UK, the Institute of Cancer Research and the Ludwig Institute. Khatereh discusses the IP in PI 3-kinases (phosphoinositide 3-kinases) that Piramed gained from that collaboration, and goes on to detail the nature and extent of the company’s collaboration with Genentech. She also outlines the company’s strategy going forward and the challenges faced by early-stage biotechs such as Piramed. http://www.pharmatelevision.com/video/521/288/pvbr_f2f44_ahmadi.m4v Tue, 30 Oct 2007 00:00:00 -0000 Business no 18:50 Piramed Pharma, Khatereh Ahmadi, biotech, pharma, cancer, early-stage biotech PharmaVentures Ltd Interview with Thomas Seoh Interview with Thomas Seoh In this week’s exclusive interview, live from Geneva, Fintan Walton talks to Thomas Seoh, CEO of France’s Faust Pharmaceuticals, a company focused on CNS disorders. Thomas starts by giving some company background, then talks about the way that Faust focuses on three types of compound – repurposed, repositioned and NCE – and about how the company’s strategy is to raise capital from the first two types to fund the third. The discussion covers the company’s two key compounds and recent issues surrounding their development. In particular, Thomas explains how the company’s strategy around its lead Parkinson’s disease compound, FP0011, has changed following the receipt of an unexpected preclinical safety signal, and how Faust is now seeking funding and a partner to take the compound through to Phase IIb and beyond. http://www.pharmatelevision.com/video/521/288/pvbr_f2f43_seoh.m4v Tue, 23 Oct 2007 00:00:00 -0000 Business no 16:20 repositioning, repurposing, generic, Parkinson's, Faust, biotech, pharma, CNS, neurological, thomas seoh PharmaVentures Ltd Interview with Rainer Wessel Interview with Rainer Wessel In this exclusive interview, Fintan Walton talks to Rainer Wessel, CEO of Ganymed Pharma, about the formation of the company and the development of its antibody therapeutics. Dr Wessel discusses the company's aim of creating products with blockbuster potential that will have an impact on the solid cancer antibody market, and the strategy through which it intends to achieve this. He describes the reasoning behind the April 2004 deal with Genmab in which Ganymed's GT43 cancer target was out-licensed, as well as the possibility of forming partnerships for the company's other products once they have shown proof-of-concept in man at Phase II/III, so that value has been created. In addition, Dr Wessel talks about the recent closing of Ganymed's Series C financing round, plans to float the company in the future, and how acquisition approaches may be considered at some point if the offer is right. Finally, he briefly touches on the current state of biotech in Europe. http://www.pharmatelevision.com/video/521/288/pvbr_f2f42_wessel.m4v Tue, 16 Oct 2007 00:00:00 -0000 Business no 13:54 antibody, rainer wessel, genmab, biotech, pharma, ganymed, cancer PharmaVentures Ltd Interview with Graziano Seghezzi Interview with Graziano Seghezzi In this second exclusive interview live from Geneva, Fintan Walton talks to Graziano Seghezzi, Partner at France-based venture capital (VC) firm Sofinnova Partners. With about half of the firm’s investments placed in the life sciences, Graziano talks about the company’s established and successful, if somewhat unusual, strategy to finance only early-stage companies. Actelion is given as an example of one of its success stories. The discussion moves on to the subject of exit strategies, and whether acquisition is a viable alternative to IPO. Graziano gives his opinion on how the European IPO market is faring at present, as well as how the European biotech sector is doing as a whole and why it has become increasingly attractive to US investors. http://www.pharmatelevision.com/video/521/288/pvbr_f2f41_graziano.m4v Tue, 09 Oct 2007 20:46:38 -0000 Business no 21:13 Venture capital, investment, biotech, pharma PharmaVentures Ltd Interview with Andrew Wood Interview with Andrew Wood In this exclusive interview, live from Geneva, Fintan Walton talks to Andrew Wood, Executive Director, Global External R&D Europe at Eli Lilly & Co. They start by talking about Andrew's function within Lilly and the company's strategy to partner not only within its main areas of therapeutic focus, but also to be open to new opportunities or 'white space'. They go on to discuss Lilly's philosophy around R&D, and how current trends in the deal landscape, such as a move towards earlier stage deals and company acquisitions, may affect its partnering activities. Andrew also talks about how the establishment of Lilly's Alliance Management system has helped the company to be a good and competitive partner. Finally, differences between opportunities in the US and Europe are considered, as well as the challenges facing Andrew and his team going forward. http://www.pharmatelevision.com/video/521/288/pvbr_f2f40_wood.m4v Tue, 02 Oct 2007 00:00:00 -0000 Business no 21:13 Eli Lilly, Europe, pharma, investment, biotech, alliance management PharmaVentures Ltd Interview with Matthew Frohn Interview with Matthew Frohn In this exclusive interview, Fintan Walton talks to Matthew Frohn, Director of Oxford Technology Management about seed capital investment in technology companies. Matthew begins by explaining Oxford Technology Management's investment strategy to date and the sorts of companies in which he is looking to invest. They discuss the different timelines to commercialisation that affect new companies in different industry sectors, with IT companies more likely to generate revenues in the short-term than life science companies, thus supporting a diversified investment portfolio. The requirements to be successful and to get to the next round of financing are also considered, with Matthew explaining that he looks for milestones that need to be achieved in order to de-risk the technology. http://www.pharmatelevision.com/video/521/288/pvbr_f2f39_frohn.m4v Tue, 04 Sep 2007 00:00:00 -0000 Business no 17:43 seed capital, venture capital, investment, technology, oxford, biotech PharmaVentures Ltd Interview with John Wyatt Interview with John Wyatt In this special feature interview, Fintan Walton talks with John Wyatt, Head of Commercial Development at PharmaVentures, about PharmaVentures' new service - PharmaDeals Research. John explains that PharmaDeals Research was launched to complement PharmaDeals Agreements in response to frequent customer requests for help with their deal-related research. These requests, John explains, were frequently from licensing executives who were too busy to carry out their own research and were looking for cost-effective information with a rapid turn-around. In particular, the service is designed to fit between the PharmaDeals Agreements deals database, and the deals and alliances consultancy services offered by PharmaVentures. They discuss that the interest to date has ranged from small biotechs who quickly need one-off pieces of research, through to big pharma companies who are looking for retained, out-sourced analytical services. To date, John mentions, the most popular service has been Benchmarking Reports. http://www.pharmatelevision.com/video/521/288/pvbr_ep13_f2f_john_wyatt.m4v Thu, 23 Aug 2007 00:00:00 -0000 Business no 5:13 PharmaDeals Research, PharmaVentures, benchmark, bechmarking, deals, alliances PharmaVentures Ltd Interview with Elias Papatheodorou Interview with Elias Papatheodorou In this exclusive interview, Fintan Walton talks to Elias Papatheodorou, CEO of novosom, about the company's novel liposomal technology, and the potential applications of this technology. Elias explains how novosom's liposomes differ from those of competitors, and how the technology could provide an alternative to antibodies in the targeting of CD40 cells. The basis and strategy behind novosom's agreements with Isis and other companies are also discussed. In addition, Elias talks about novosom's current financing drive to fund the company's activities. http://www.pharmaventuresbusinessreview.com/media/pvbr_f2f38_papatheodorou.m4v Tue, 07 Aug 2007 00:00:00 -0000 Business no 12:56 Elias Papatheodorou, novosom, Liposome, Drug delivery PharmaVentures Ltd Interview with Johanna Holldack Interview with Johanna Holldack In this exclusive interview, Fintan Walton talks to Johanna Holldack, CEO of Borean Pharma. The conversation begins with a discussion on the unique aspects of Borean's proprietary technology, including its scaffold library, which is derived from a human protein, and whose compounds possess features that facilitate the process of their development. Johanna then discusses Borean's current strategy of developing its lead molecules for entry into clinical trials in 2009. The 2006 product acquisition deal between Borean and F. Hoffmann-La Roche is also discussed, and Johanna explains why Roche may have been interested in acquiring one of Borean's lead candidates. The interview then turns towards the state of the biotech industry in Denmark, and how this is backed by innovative research, especially in the field of protein engineering, that is taking place in the Denmark's research institutes and universities. The importance of international investors to small biotech companies is covered, and the interview concludes with Johanna's speculation on whether the company will undergo an IPO or an acquisition. http://www.pharmaventuresbusinessreview.com/media/pvbr_f2f37_holldack.m4v Tue, 31 Jul 2007 12:00:00 -0000 Business no 12:27 Johanna Holldack, Borean, Recombinant protein, Danish, Biotech PharmaVentures Ltd Interview with Tom Rademacher Interview with Tom Rademacher In this exclusive interview, Fintan Walton talks to Tom Rademacher, President of Midatech, about the formation of the biotech, Professor Rademacher's fifth start-up company. Tom discusses Midatech's business model, and why a centralised group company structure with three fully owned subsidiaries suited the development of its technology. He also talks in depth about the science behind the company's nanoparticle technology, as well as its applications in therapeutics, diagnostics and surface coatings. http://www.pharmaventuresbusinessreview.com/media/pvbr_f2f36_rademacher.m4v Tue, 24 Jul 2007 12:00:00 -0000 Business no 13:08 Tom Rademacher, Midatech, biotech, nanoparticle, Fintan Walton PharmaVentures Ltd The Fourteenth Edition of PharmaVentures Business Review World's first pharmaceutical business show Welcome to the July 2007 edition of the PharmaVentures Business Review. In the Business Report we investigate the trends surrounding upfront payments in licensing deals. In the Month in Review, we review the industry's key deals during June 2007 and their likely impact on the companies involved as well as on the market sector. In Face-to-Face, Fintan Walton talks to Tim Zeppenfeld, Business Development Manager, Gene Bridges about life as a self-funded and profitable emerging biotechnology company in Germany. http://www.pharmatelevision.com/media/pvbr_ep14_full.m4v Tue, 17 Jul 2007 00:00:00 -0000 Business no 34:45 gene bridges, zeppenfeld, dna, biotech, pharmaceutical, television, business, deals, licensing, mergers, financing, acquisitions, commentary, pharmadeals, generics, valuation, review PharmaVentures Ltd Interview with Tim Zeppenfeld Interview with Tim Zeppenfeld Fintan Walton talks to Tim Zeppenfeld, Business Development Manager, Gene Bridges, about life as a self-funded and profitable biotechnology company. Tim tells Fintan about Gene Bridges' Red/ET technology and describes the licensing, fee-for-service and kit distribution business models that the company is following. They discuss Gene Bridge's alliance with BASF, and Tim emphasises the importance of this alliance as a model for an evolving relationship from fee-for-service to a fully blown collaboration. Highlighting Gene Bridge's unusual position as a self-funded and profitable emerging biotechnology company, Tim shares his thoughts on the consolidation of the biotech sector in Germany, and speculates as to Gene Bridges' future strategy. http://www.pharmatelevision.com/media/pvbr_f2f35_zeppenfeld.m4v Tue, 17 Jul 2007 00:00:00 -0000 Business no 13:16 Gene Bridges, biotech, funding PharmaVentures Ltd Interview with Ian Wisenberg Interview with Ian Wisenberg In this exclusive interview, Fintan Walton talks to Ian Wisenberg, SVP of Business Development and CFO of BIOCOM, about the association's role in promoting Southern Californian life sciences companies. Mr Wisenberg explains the differences between the life sciences community in North and South California. In particular he emphasises South California's presence in early-stage drug discovery. The need for capital to maintain the growth of South California's life sciences community is discussed and Mr Wisenberg highlights the success that BIOCOM companies have had in raising capital so far in 2007. The challenge for Southern Califorian companies, Mr Wisenberg explains, is for these early-stage discovery companies to make the transition to mature, established companies. http://www.pharmaventuresbusinessreview.com/media/pvbr_f2f34_wisenberg.m4v Tue, 10 Jul 2007 00:00:00 -0000 Business no 13:05 BIOCOM, Southern Californian, Califfornia, biotech, Amgen, topotarget, amylin PharmaVentures Ltd Interview with Brian Beglin Interview with Brian Beglin Fintan Walton talks to Brian Beglin, a partner at Bingham McCutchen. The interview begins with a discussion of the strengths of the markets at this present time, of the surge in M&A activity combined with the reduction in company IPOs, and of the appeal for foreign companies to be listed in US markets. It moves on to look at the very active area of PIPES (private investment in public equities), and why this option may be more attractive to non-US companies who are prepared to issue shares to US investors. The increase in available capital to companies with products that are at least in Phase II-Phase IIb development is covered, followed by a more detailed examination of M&A deals, and how these can transition from what may initially have been partnering talks. The issues associated with non-US companies making acquisitions in the US are considered, followed by the strategies that these companies might employ to acquire co-promotion rights in the US. The interview concludes with Brian's prediction for which types of deals will be the primary focus for biotech companies in the coming year. http://www.pharmaventuresbusinessreview.com/media/pvbr_f2f33_beglin.m4v Tue, 26 Jun 2007 00:00:00 -0000 Business no 15:40 Brian Beglin, Bingham McCutchen PharmaVentures Ltd Interview with Arthur Sands Interview with Arthur Sands In this exclusive interview, Fintan Walton talks to Arthur Sands, President and Chief Executive Officer of Lexicon Pharmaceuticals, about the company's recent name change from Lexicon Genetics and how this signals a shift from drug discovery to clinical development. Dr Sands discusses Lexicon's deals with Genentech and Bristol-Myers Squibb (BMS), and the ways in which the company captures long-term value in these partnerships. Also detailed is the science behind Lexicon's programmes and the strategy going forward as the company moves its first products into clinical development, including the goal of advancing ten drug candidates into human clinical trials by the end of 2010. http://www.pharmaventuresbusinessreview.com/media/pvbr_f2f32_sands.m4v Tue, 19 Jun 2007 00:00:00 -0000 Business no 16:48 Lexicon Pharmaceuticals, Arthur Sands PharmaVentures Ltd Interview with Joseph McCracken Interview with Joseph McCracken In this exclusive interview, Fintan Walton talks to Joseph McCracken, Vice President of Business Development at Genentech, about the strategy and drivers behind the company's various licensing and collaboration deals. Joseph describes the benefits of a partnership with Genentech: namely, its dynamic and innovative approach, and the economies of scale and expertise that result from its large size. Also detailed are the alliance management techniques used by Genentech in its various collaborations. In addition, Joseph talks about Genentech's approach to the spin-out companies it generates when promising work falls outside its therapeutic areas of focus. http://www.pharmaventuresbusinessreview.com/media/pvbr_f2f30_mccracken.m4v Tue, 12 Jun 2007 00:00:00 -0000 Business no 17:36 Joseph McCracken, Genentech PharmaVentures Ltd Interview with Jeremy Levin Interview with Jeremy Levin In this exclusive interview, Fintan Walton talks to Jeremy Levin, Global Head of Strategic Alliances for the Novartis Institutes for BioMedical Research (NIBR), about the switch in the location of NIBR's headquarters from Switzerland to Cambridge, Massachusetts. Jeremy explains Novartis' desire to create a company that combines the innovation of its surrounding biotech community with the established drug discovery and development capabilities of a pharmaceutical company. He also describes the challenges involved in maintaining the 400 collaborations with 120 biotech companies in over 22 countries that Novartis has entered into since 2003. In addition, Jeremy outlines the benefits of fusing the multitude of skills, technologies and capabilities of biotech companies, and discusses the rationale behind Novartis' deal making. http://www.pharmaventuresbusinessreview.com/media/pvbr_f2f29_levin.m4v Tue, 05 Jun 2007 00:00:00 -0000 Business no 22:54 Jeremy Levin, Strategic Alliances, Novartis, NIBR PharmaVentures Ltd Interview with Eric de La Fortelle Interview with Eric de La Fortelle In this exclusive interview, Fintan Walton talks to Eric de La Fortelle, Global Head, External Research and Technology, F. Hoffman-La Roche, about the global restructuring of Roche's research and development activities, which is due to be implemented on 2 July 2007. Eric explains that Roche has taken the decision to improve its R&D model at a time of strength, when its financial results are proving excellent, in order to adapt to a changing environment in which demands are increasing from both patients and regulators. In the interview, Eric describes how Roche R&D will be organised into five Disease Biology Areas (DBAs), and how these DBAs will be managed. He also explains the research and development tensions that can be resolved by this new model. Just how these changes will affect partnering with Roche is discussed as well, highlighting the integrated role that the Roche Pharma Partnering group, to be led by the incoming Dan Zabrowski, will have with the new DBAs. http://www.pharmaventuresbusinessreview.com/media/pvbr_f2f28_fortelle.m4v Tue, 29 May 2007 00:00:00 -0000 Business no 20:50 Eric de La Fortelle, F. Hoffman-La Roche, Roche, R&D, Research and Development, partnering PharmaVentures Ltd Interview with Jim Greenwood Interview with Jim Greenwood In this interview, Fintan Walton talks to Jim Greenwood, President and CEO of the Biotechnology Industry Organization (BIO), about the issues and threats facing the biotechnology industry today. Jim begins by referring to the large number of delegates at the BIO International Convention and how this reflects on the growth of the biotech industry as a whole. He then discusses the impact of the Democrat majority in the US House of Representatives and Senate on the biotech and pharmaceutical industry. The challenges that BIO faces in changing the somewhat negative public perception of the biotech and pharma industry – and in making the public understand why drugs can be so expensive – are also considered. The interview then moves on to the subject of the recent increase in company acquisitions, and why this is beneficial to both small innovative companies, and to global pharma companies. Among other things, Fintan and Jim also talk about the trend in outsourcing to India and China, the move by academics towards more commercially viable research, and the drop in drug prices that will undoubtedly happen. The interview ends with Jim’s vision for the future, with particular reference to the enormous potential of RNAi technology to the industry. http://www.pharmaventuresbusinessreview.com/media/pvbr_f2f35_greenwood.m4v Tue, 22 May 2007 00:00:00 -0000 Business no 19:07 Jim Greenwood, BIO, biotech industry, biotchnology industry, BIO International Convention PharmaVentures Ltd An Interview with Nick Woolf, SVP Corporate Strategy, Oxford BioMedica An Interview with Nick Woolf, SVP Corporate Strategy, Oxford BioMedica Fintan Walton talks to Nick Woolf, Senior Vice President, Corporate Strategy, Oxford BioMedica, about the company's ongoing success as it moves toward its ultimate goal of becoming a fully integrated specialty pharmaceutical company. They review the company's history and the finances that have been raised since its successful public listing on AIM in 1996. Together, they discuss the challenges of operating within the gene therapy space, and how Oxford BioMedica has leveraged value from its viral vector technology through deal making. Nick also talks about Oxford BioMedica's recent acquisition of Oxxon Therapeutics, and the landmark deal the company has signed with global giant sanofi-aventis to complete the development of its lead product, the cancer vaccine TroVax. http://www.pharmaventuresbusinessreview.com/media/pvbr_f2f26_woolfm4v Mon, 21 May 2007 16:35:13 -0000 Business no 22:14 Oxford BioMedica, Nick Woolf PharmaVentures Ltd Interview with Nigel Borshell Interview with Nigel Borshell In this special interview, Fintan Walton talks to independent pharmaceutical consultant, Nigel Borshell, about the relevance of pricing and reimbursement (P&R) to deal-making within the industry. http://www.pharmaventuresbusinessreview.com/media/pvbr_f2f33_borshell.m4v Tue, 15 May 2007 17:12:31 -0000 Business no 19:39 Nigel Borshell, Pricing, Reimbursement, P&R PharmaVentures Ltd The Thirteenth Edition of PharmaVentures Business Review World's first pharmaceutical business show In the fifth PharmaVentures Business Review of 2007, we take a look at the generics sector of the pharmaceutical industry. In the Business Report, we investigate the trends in deal making for the generics sector and discuss the types of deals that make it unique - compared with the rest of the pharmaceutical industry. In the Month in Review, we review the industry's key deals during April 2007 and their likely impact on the companies involved as well as on the market sector. In Face-to-Face, Fintan Walton talks to Nick Woolf, Senior Vice President, Corporate Strategy, Oxford BioMedica, about the company's ongoing success as it moves toward its ultimate goal of becoming a fully integrated specialty pharmaceutical company. http://www.pharmatelevision.com/media/pvbr_ep13_full.m4v Tue, 08 May 2007 00:00:00 -0000 Business no 42:52 oxford biomedica, sanofi-aventis, trovax, gene therapy, cancer, biotech, pharmaceutical, television, business, deals, licensing, mergers, financing, acquisitions, commentary, pharmadeals, generics, valuation, review PharmaVentures Ltd Interview with Gerard Fairtlough Interview with Gerard Fairtlough In this second interview of a two-part series, Fintan Walton talks to Gerard Fairtlough, founder & former CEO of Celltech, about his views regarding the alternatives to hierarchy within companies. Gerard explains that most people consider that hierarchy is required to make large organisations work effectively and that when things are not going as planned, it is usually the top of the hierarchy that is changed, be that the CEO of a pharmaceutical company or the manager of a football club. However, what Gerard proposes is that the best environment to manage an entrepreneurial organisation requires one of the "Three Ways of Getting Things Done" (1) hierarchy, (2) heterarchy or (3) responsible autonomy. Gerard argues that the pharmaceutical industry needs to copy the biotech ethos, and use independent units, with little bureaucratic control, to achieve defined tasks. In order for companies to take full advantage of industry globalisation, organisations of all sizes should look towards heterarchy. http://www.pharmatelevision.com/media/pvbr_f2f27_fairtlough2.m4v Tue, 08 May 2007 00:00:00 -0000 Business no 10:42 gerard fairtlough, celltech, biotechnology, deal making, negotiatings, business development, sales, in-licensing, out-licensing, competitive intelligence, market surveys PharmaVentures Ltd An interview with Tom Quinlan and Matthew Gardner An interview with Tom Quinlan and Matthew Gardner This week, Fintan Walton seeks the opinions of Tom Quinlan, Partner at Reed Smith, and Matthew Gardner, President at BayBio, on the state of the industry in 2006 and how they see 2007 developing. Initially, the panellists discuss the high number and differing types of deals that took place in 2006, and consider how they expect this to continue in the foreseeable future and the drivers behind this. Also covered is the impact of company acquisitions and the effect these have on their local regions, with Matthew giving examples specific to Northern California. The debate moves on to the impact of the Sarbanes-Oxley Act in 2006 and the potential opening up of the market in 2007 due to the expected loosening of restrictions and the opportunities that may arise from this. Further topics include patent infringement issues, specifically the MedImmune v. Genentech case, and the impact of the US Democrats being the majority party in the US Senate as well as in the House of Representatives. The discussion closes with both Matthew and Tom giving their predictions for 2007. http://www.pharmaventuresbusinessreview.com/media/ptv_us_perspective.m4v Tue, 01 May 2007 00:00:00 -0000 Business no 21:18 Tom Quinlan, Thomas Quinlan, Thomas J. Quinlan, Matt Gardner, Matthew Gardner, Matthew M. Gardner, BayBio, Reed Smith, Sarbanes-Oxley, Biotech 2007, Biotechnology 2007, South San Francisco, Northern California PharmaVentures Ltd An interview with Jeremy Curnock Cook, John Wilkinson and Jim McCarthy An interview with Jeremy Curnock Cook, John Wilkinson and Jim McCarthy Fintan Walton talks to Jeremy Curnock Cook, Bioscience Managers, John Wilkinson, Reed Smith, and Jim McCarthy, PharmaVentures, about the state of the industry in 2006 and what's likely to happen in 2007. The panellists start by discussing how 2006 saw significant funds transferring from pharma to biotech companies, with numerous mergers and acquisitions, and the establishment of many corporate relationships. The IPO market remains a challenge, and biotech CEOs are looking increasingly for alternative ways into the market. The experts discuss why this is the case, the alternative approaches being taken and the impact that this has on deal value. Discussion surrounding the business model of family-run pharma companies is included, as is the trend for more complex deals, which rely greatly on good relationship management after a transaction has been completed. To find out what the panellists predict for 2007, watch the interview. http://www.pharmaventuresbusinessreview.com/media/ptv_eu_perspective.m4v Mon, 23 Apr 2007 00:00:00 -0000 Business no 28:07 Acquisition of biotechs, AIM, Sarbanes-Oxley, high value deals, transactions, relationship management, confidence in public markets, strategic fit, VC investment hurdles, speciality pharma, mid-sized family-run businesses in Europe, cultural issues in dea PharmaVentures Ltd Interview with Damian Marron Interview with Damian Marron Fintan Walton talks to Damian Marron, Vice President, Corporate Development, NicOx, about the company's achievements to date - from Italian origins, it developed into a rare French biopharmaceutical success story, raising some of the largest capital sums in Europe. Damian discusses NicOx's strategy with regards to attracting investors, choice of stock exchange and the rationale behind its partner selection. Also outlined are the company's objectives, ranging from its plans for the next 12 months to its long term aims regarding its conversion to a partially integrated pharmaceutical company. http://www.pharmatelevision.com/media/pvbr_ep12_3.m4v Thu, 19 Apr 2007 00:00:00 -0000 Business no 21:58 nicox, cardiovascular, biotech, pharmaceutical, television, business, deals, licensing, mergers, financing, acquisitions, commentary, pharmadeals, valuation, review PharmaVentures Ltd Interview with Gerard Fairtlough Interview with Gerard Fairtlough This month, Fintan Walton talks to Gerard Fairtlough, founder & former CEO of Celltech, about the story behind the company and the drivers that enabled Celltech to establish itself as Europe's first biotechnology company. Gerard explains that balancing the pressures of profitability and innovation were key factors of Celltech's success. At that time investors weren't accustomed to biotechnology companies going through several rounds of financing; therefore, the company used manufacturing as a means of financing its projects. Alongside the issue of profitability, the company was frequently asked to work on new ventures. However, it had to be careful about what was taken on in order to maintain focus. Collaborations played a significant part of the firm's growth, providing money, enhancing skills and building a reputation. http://www.pharmatelevision.com/media/pvbr_f2f25_fairtlough.m4v Mon, 16 Apr 2007 12:00:00 -0000 Business no 26:27 gerard fairtlough, celltech, biotechnology, deal making, negotiatings, business development, sales, in-licensing, out-licensing, competitive intelligence, market surveys PharmaVentures Ltd The Twelfth Edition of PharmaVentures Business Review World's first pharmaceutical business show In the fourth PharmaVentures Business Review of 2007, we focus on the cardiovascular sector. In the Business Report, we take a look at the current status of the cardiovascular therapy market and investigate the trends in deal making throughout the last decade for this major segment of the pharmaceutical industry. In the Month in Review, we review the industry's key deals during March 2007 and their likely impact on the companies involved as well as the market sector. In Face-to-Face, Fintan Walton talks to Damian Marron, Vice President, Corporate Development, NicOx, about the company's achievements to date and its ambitious plans for the future. http://www.pharmatelevision.com/media/pvbr_ep12_full.m4v Mon, 09 Apr 2007 12:00:00 -0000 Business no 41:54 nicox, cardiovascular, biotech, pharmaceutical, television, business, deals, licensing, mergers, financing, acquisitions, commentary, pharmadeals, valuation, review PharmaVentures Ltd Interview with Krishnan Nandu Nadabalan and Vimal Mehta Interview with Krishnan Nandu Nandabalan and Vimal Mehta Fintan Walton, talks to Vimal Mehta and Krishnan 'Nandu' Nandabalan, Chairman and President and CEO, respectively, of BioXcel Corporation, about how the company is uniquely positioned to take advantage of the growing need for western and Indian healthcare companies to work with one another. The discussion covers why Indian healthcare companies are set to become major players in the global industry and the factors that gave rise to this. Vimal describes how he sees the mentality of the Indian pharmaceutical industry shifting as it becomes both willing and able to develop innovative molecules in order to compete in a global market. With the risks involved in the biotechnology and pharmaceutical sectors, Nandu gives several reasons why India provides a good opportunity for drug development. India offers a larger pool of potential patients in addition to a well-established clinical infrastructure, an existing healthcare industry with high standards and a history of manufacturing. Capital is also available as a result of the dot.com software and services boom, but also from the Indian government which views biotechnology and pharmaceutical as the next big development area. The interview also covers how BioXcel is set up to facilitate these partnerships and how its business solutions are aiming to provide it. Nandu explains how BioXcel has established facilities in the US and India, with the US office managing the corporate activities while the research, analysis and data mining takes place in India. This enables the organisation to combine the business experience of the west with the rich, emerging skills base in India. http://www.pharmatelevision.com/media/pvbr_f2f24_nandabalan_mehta.m4v Mon, 02 Apr 2007 00:00:00 -0000 Business no 17:26 Vimal Mehta, Krishnan Nandabalan, BioXcel Corporation, Indian Healthcare, Indian, Pharmaceutical, Indian Biotechnology, India, Deal making, Negotiatings, Business development, Sales, In-licensing, Out-licensing, Competitive intelligence, Market surveys PharmaVentures Ltd Special Interview with Bruce Carter Interview with Bruce Carter This month, Fintan Walton, talks to Bruce Carter, CEO of ZymoGenetics, about the story behind the development and growth of ZymoGenetics. He discusses the company's fascinating 26-year history and its worldwide impact on insulin. The interview also covers the factors influencing successful innovation and the implications of big pharma working with, or acquiring, biotechs. Bruce describes the significant role that Novo Nordisk played in ZymoGenetics' position today, explaining that ZymoGenetics, although successfully scientifically, was in managerial disarray. The company was led by six presidents in just five years, resulting in the business being starved of capital. Novo Nordisk acquired the company in 1988 and divested it 12 years later. Bruce also gives his view on how big pharmaceutical companies should approach acquiring a biotechnology company. Using the analogy of choosing a spouse, Bruce argues that, if you initially find something attractive, do not set out to change that. Fintan also questions Bruce on what he thinks is the best culture for innovation, to which Bruce responds that naivety is key. For example, he argues that bureaucracy is not the real reason why innovation is more difficult in a large pharma company, rather that, because they are so big, there is always someone, somewhere who has a perfectly rational reason for why something will not work. Finally, Bruce outlines ZymoGenetics' future, with regards to therapy area and potential acquisitions. http://www.pharmatelevision.com/media/pvbr_f2f23_carter.m4v Mon, 26 Mar 2007 00:00:00 -0000 Business no 18:12 Bruce Carter, ZymoGenetics, Insulin, Novo Nordisk, Innovation, Protein, Big Pharma, Big pharmaceutical company, Biotechnology, Biotech PharmaVentures Ltd Special Interview with IPSO Ventures Interview with Simon Hunt and Nick Rodgers Fintan Walton talks to Simon Hunt and Nick Rodgers, Executive Chairman and Chief Executive of Ipso Ventures, about founding their company in 2005 and their business model for the future. Simon and Nick explain how they set up the firm to capitalise on their background in venture capital and investment banking. With their prior experience, the founders have identified the need to reduce risk in early stage companies, such as university spin-outs. By establishing relationships with universities that have good commercialisable IP they aim to add value and build stronger businesses. The company's first deal is with Loughborough University, which has a successful track record in spin-out formation. Ipso Ventures are also investing in a range of university spin-outs, in the hope that these will build further relationships with academic institutions. To date, Ipso Ventures has invested in technologies from Imperial College, London, The School of Pharmacy, London and Oxford Brookes University. Ipso Ventures' plan for the future includes establishing up to eight relationships with universities within three years. By spreading their risk across a range of companies, they have an opportunity to add value, while further building their own business. http://www.pharmatelevision.com/media/pvbr_f2f21_simon_nick.m4v Tue, 13 Mar 2007 12:00:00 -0000 Business no 16:02 Simon Hunt, Nick Rodgers, Ipso Ventures, corporate finance, university relationships, Loughborough University, investment, building businesses, life sciences, consultants, PharmaVentures Ltd The Eleventh Edition of PharmaVentures Business Review World's first pharmaceutical business show In the third PharmaVentures Business Review of 2007, we focus our attention on the drug discovery sector. In the Business Report, we take a look at some of the key trends in drug discovery deal making across the past five years and review the key stages of the drug discovery process as well as the key technologies that have been boosting deal making in this important sector of the pharmaceutical market. In the Month in Review, we review the industry's key deals during February 2007 and their likley impact on the companies involved and the market sector. In Face-to-Face, Fintan Walton talks to Tim Mitchell, of Sareum, about the company's set up, its future plans for internal product development and fee-for-service. http://www.pharmatelevision.com/media/pvbr_ep11_full.m4v Sat, 10 Mar 2007 00:00:00 -0000 Business no 36:42 biotechnology, biotech, pharmaceutical, television, business, deals, licensing, mergers, financing, initial public offering, ipo, acquisitions, commentary, pharmadeals, valuation, review PharmaVentures Ltd Special Interview with Implicit Bioscience- March 2007 Fintan Walton talks to Dick Haiduck about his work with Implicit Bioscience, Cytopia and others, and his 'partner to CEO' service. Dick describes these two different companies - both based in Australia - and their product offerings. The companies are at different stages of development, and therefore have different requirements: Implicit Bioscience is focused on immunology-based drug development, while Cytopia focuses on JAK (Just Another Kinase) inhibitors for cancer treatment. A third company that Dick works with focuses on a point-of-care hydration measurement tool. Dick, who is CEO of Implicit Bioscience, US Operations, talks about the founding of the firm in 2004; this was based on the principle that quality people are critical to driving success. The company's business model, which initially involved acquiring assets to a compound previously tested for a different indication, and exploring how new technology can overcome the problems encountered during clinical development, is particularly interesting. Following a brief discussion of Dick's industry experience, Fintan asks him about the biotech landscape today, the trend of pharma buying up biotech firms and access to capital for firms. Despite the challenges that the industry faces, Dick assures us that the combination of entrepreneurship and good science in the US are irrepressible, and that these will, inevitably lead to success, even if CEOs have to become increasingly creative. http://www.pharmatelevision.com/media/pvbr_f2f21_haiduck.m4v Mon, 05 Mar 2007 12:00:00 -0000 Business no 21:44 Implicit Bioscience, partner to CEO, dick haiduck, immunology, oglufanide disodium, influenza, immunomodulator, grant funding, US Operations, accelerating value creation, access to capital, creative, strategy, proven safety, entrepreneurship, cytopia PharmaVentures Ltd Interview with Tim Mitchell Interview with Tim Mitchell Sareum and Structure: An Interview with Tim Mitchell, CEO, Sareum Zero segment text: Fintan Walton talks to Tim Mitchell, CEO, Sareum, about founding the company with David Williams and John Reader, as a spin-out from Millennium Pharmaceuticals' Structure-based Discovery Department. Tim explains how the company's success is based on the excellent track record and relationships the management established at Millennium Pharmaceuticals and at Cambridge Discovery Chemistry and the efficient structure-based drug discovery services they have refined over the years. http://www.pharmatelevision.com/media/pvbr_ep11_3.m4v Thu, 01 Mar 2007 00:00:00 -0000 Business no 14:14 biotechnology, biotech, pharmaceutical, television, business, deals, licensing, mergers, financing, initial public offering, ipo, acquisitions, commentary, pharmadeals, valuation, review PharmaVentures Ltd Special Interview with Charles Potter, Glide Pharma Interview with Charles Potter Fintan Walton talks to Charles Potter, CEO, Glide Pharma, about inventing the Glide technology and his subsequent setting up of Glide Pharmaceutical Technologies. After covering Charles' experience at PowderJect Pharmaceuticals, Fintan and Charles discuss how the company, originally set up as the drug delivery firm Caretek Medical, evolved into a specialty pharmaceutical company. Today, Glide Pharma has three generic products in its pipeline, in addition to partnerships that include one with a top five pharmaceutical company. These applications of the Glide technology have been applied only to products already available on the market, but this may change as the company moves forward. Glide's financial backing includes support from Oxford Venture Capital Trust and other local business angels. Impressively, the last equity financing closed just 4weeks after the business plans were sent out! Glide is obviously in a good position at the moment, and expects to raise further finance after completing some internal company milestones. The opportunities for Glide at the moment are enormous. In addition to it own products and partnerships, the company's technology patent also permits it application to medical devices. For the time being, however, Glide intends to focus its efforts on its current projects. http://www.pharmatelevision.com/media/pvbr_f2f20_potter.m4v Mon, 26 Feb 2007 00:00:00 -0000 Business no 17:54 glide pharma, bioequivalence, charles potter, needle-free, drug delivery, life-cycle management, caretek medical, partner, seed funding, founder, oxford venture capital trust, business angels, strategy, product differentiation, generics, vaccines PharmaVentures Ltd Special Interview with Xanthus Interview with Mike Boss Fintan Walton talks to Mike Boss, Chief Business Officer, Xanthus Pharmaceuticals, about his role in the evolution of Xanthus, a biopharmaceutical company founded in 2001. After covering Mike's industry experience, Fintan and Mike discuss how Xanthus morphed from a personalised medicine company into a drug discovery firm, which today has five promising molecules in its product pipeline. All of the company's products are focused on the treatment of cancer and autoimmune disorders. With successful backing from a group of venture capital firms and US$25 M secured in a recent funding round, Xanthus is in a strong position. Although the firm's business strategy was originally to in-license small novel molecules and advance them to a stage where partnering can be assessed, the acquisition of new molecules has led the firm to adapt this strategy according to the stage of the product in development. For one of Xanthus' molecules, this will involve taking the product through clinical trials. http://www.pharmaventuresbusinessreview.com/media/pvbr_f2f19_boss.m4v Mon, 19 Feb 2007 12:00:00 -0000 Business no 15:40 xanthus, chief business officer, cancer, autoimmune disorders, drug development, partnering, xanafide, symadex, aml, solid tumours, clinical trials, biotechnology, business strategy, commercialisation, mike boss, personalised medicine, licensing PharmaVentures Ltd The Tenth Edition of PharmaVentures Business Review World's first pharmaceutical business show PharmaVentures Business Review is a new cutting edge television business show that provides viewers with effortless access to essential industry intelligence. As the first of its kind it is already watched by thousands throughout the pharma and biotech industry, as well as the financial sector. PharmaVentures Business Review will keep you informed with our insightful coverage of major transactions and industry trends, as well as giving you exclusive access to topical interviews with senior executives and independent expert opinions. The programme is presented by Fintan Walton, CEO of PharmaVentures and Ann Salter and comprises four distinct sections: The Month in Review - The essential details of key business transactions selected by PharmaVentures' team of experienced business analysts. The Business Report - An analysis of important industry trends in deal making, therapies and technology area. Face-to-Face - In-depth interviews providing you with an insight into the real-life workings of the deal making process. Meet the Experts - Round-table discussions giving you access to the experience of leading analysts, commentators and decision makers from various sectors of the industry worldwide. http://www.pharmaventuresbusinessreview.com/media/pvbr_ep10_full.m4v Tue, 13 Feb 2007 12:00:00 -0000 Business no 39:06 biotechnology, biotech, pharmaceutical, television, business, deals, licensing, mergers, financing, initial public offering, ipo, acquisitions, commentary, pharmadeals, valuation, review PharmaVentures Ltd Special Interview with Synosia Therapeutics Interview with Tom Woiwode Tom Woiwode, VP Business Development & Strategy, Synosia Therapeutics, talks to Fintan Walton about the launch of the firm in January 2007. They discuss the creation and launch of the firm, Synosia's relationship with Roche, raising funding in the US and Synosia's plan to launch, market and sell its own products. http://www.pharmaventuresbusinessreview.com/media/pvbr_f2f17_woiwode.m4v Mon, 05 Feb 2007 12:00:00 -0000 Business no 18:31 tom woiwode, synosia, cns, versant, roche, in-licensing, brad bolzon, pipeline, clinical trials, funding, strategy PharmaVentures Ltd Interview with John Patton Interview with John Patton Fintan Walton talks to John Patton, CSO and Co-founder of Nektar Therapeutics about the challenges he faced in setting up the firm and the company's success to date. John describes how his research at Genentech on inhaled proteins prompted him to set up Nektar (then Inhale Therapeutic Systems), and discusses the resistance he faced from traditional players in the diabetes market when seeking partners. Since its deals with GlaxoSmithKline and Pfizer in 2004 - both for Nektar's PEGylation technology - and its subsequent acquisition of Aerogen, the 1.3billion-dollar company has gone from strength to strength. John outlines the business strategy for Nektar going forward and also discusses the company's product pipeline. http://www.pharmatelevision.com/media/pvbr_ep10_3.m4v Thu, 01 Feb 2007 00:00:00 -0000 Business no 20:23 biotechnology, biotech, pharmaceutical, television, business, deals, licensing, mergers, financing, initial public offering, ipo, acquisitions, commentary, pharmadeals, valuation, review PharmaVentures Ltd The Ninth Edition of PharmaVentures Business Review World's first pharmaceutical business show PharmaVentures Business Review is a new cutting edge television business show that provides viewers with effortless access to essential industry intelligence. As the first of its kind it is already watched by thousands throughout the pharma and biotech industry, as well as the financial sector. PharmaVentures Business Review will keep you informed with our insightful coverage of major transactions and industry trends, as well as giving you exclusive access to topical interviews with senior executives and independent expert opinions. The programme is presented by Fintan Walton, CEO of PharmaVentures and Ann Salter and comprises four distinct sections: The Month in Review - The essential details of key business transactions selected by PharmaVentures' team of experienced business analysts. The Business Report - An analysis of important industry trends in deal making, therapies and technology area. Face-to-Face - In-depth interviews providing you with an insight into the real-life workings of the deal making process. Meet the Experts - Round-table discussions giving you access to the experience of leading analysts, commentators and decision makers from various sectors of the industry worldwide. http://www.pharmaventuresbusinessreview.com/media/pvbr_ep9_full.m4v Tue, 23 Jan 2007 00:00:00 -0000 Business no 39:30 biotechnology, biotech, pharmaceutical, television, business, deals, licensing, mergers, financing, initial public offering, ipo, acquisitions, commentary, pharmadeals, valuation, review PharmaVentures Ltd PharmaVentures Business Review Interview Special The Story of PharmaTelevision In an interview with Ann Salter, Fintan Walton, CEO, PharmaVentures, looks back at the successful creation of PharmaVentures Business Review and discusses its growth and development since its launch in May 2006. He highlights the aims and strategy surrounding the formation of PharmaTelevision and outlines his plans to expand and develop the concept in 2007, with the addition of new channels and even more content. http://www.pharmaventuresbusinessreview.com/media/pvbr_f2f_fintan_ann.m4v Wed, 17 Jan 2007 12:00:00 -0000 Business no 12:26 Fintan Walton, PharmaVentures, PharmaTelevision, PharmaVentures Business Review PharmaVentures Ltd Pharmaventures Business Review Special An interview with Colin Dawson of Otago Innovation and David Williams of Chemeq In this 'Meet the Experts' special, Fintan Walton is joined on the panel by Colin Dawson, CEO of Otago Innovation and David Williams, CEO of Chemeq. Together, they discuss a variety of important issues that face the biotechnology industry in Australia and New Zealand. They talk about the current climate for early-stage financing of start-up companies and the problems that many companies have when they enter the public markets via the ASX. They also talk about the bidirectional opportunities for partnering Australian or New Zealand companies with their European, US and South-East Asian counterparts. http://www.pharmaventuresbusinessreview.com/media/pvbr_f2f9_williams_dawson.m4v Mon, 15 Jan 2007 12:00:00 -0000 Business no 21:25 Fintan Walton, Colin Dawson, Otago Innovation, David Williams, Chemeq, biotechnology, Australia, pharmaceutical, business, licensing, mergers, financing, initial public offering, ipo, acquisitions, pharmadeals, valuation PharmaVentures Ltd The Eighth Edition of PharmaVentures Business Review World's first pharmaceutical business show PharmaVentures Business Review is a new cutting edge television business show that provides viewers with effortless access to essential industry intelligence. As the first of its kind it is already watched by thousands throughout the pharma and biotech industry, as well as the financial sector. PharmaVentures Business Review will keep you informed with our insightful coverage of major transactions and industry trends, as well as giving you exclusive access to topical interviews with senior executives and independent expert opinions. The programme is presented by Fintan Walton, CEO of PharmaVentures and Ann Salter and comprises four distinct sections: The Month in Review - The essential details of key business transactions selected by PharmaVentures' team of experienced business analysts. The Business Report - An analysis of important industry trends in deal making, therapies and technology area. Face-to-Face - In-depth interviews providing you with an insight into the real-life workings of the deal making process. Meet the Experts - Round-table discussions giving you access to the experience of leading analysts, commentators and decision makers from various sectors of the industry worldwide. http://www.pharmaventuresbusinessreview.com/media/pvbr_ep8_full.m4v Sat, 16 Dec 2006 12:00:00 -0000 Business no 39:27 biotechnology, biotech, pharmaceutical, television, business, deals, licensing, mergers, financing, initial public offering, ipo, acquisitions, commentary, pharmadeals, valuation, review PharmaVentures Ltd Australia Biotech Special 2006 - December 2006 Interview with Dr Anna Kluczewska, Managing Director, AION Diagnostics Dr Anna Kluczewska talks to Fintan Walton about how the Australian AION diagnostics was set up as a spin-out from pSivida (of which it is a subsidiary), based on novel BioSilicon. technologies. They discuss AION's business model, divestment plans and long-term goal of focusing on becoming a molecular imaging-based company. Anna explains the expansion of the company's operations into the US as well as its intention to develop its diagnostics business via the formation of collaborations. She also outlines the key challenges that AION faces over the next few years. http://www.pharmaventuresbusinessreview.com/media/pvbr_f2f12a_kluczewska.m4v Fri, 15 Dec 2006 12:00:00 -0000 Business no 18:12 fintan, walton, Anna Kluczewska, AION Diagnostics, biotechnology, AusBiotech, Australia, pharmaceutical, television, business, deals, licensing, mergers, financing, initial public offering, ipo, acquisitions, pharmadeals, valuation, review PharmaVentures Ltd Australia Biotech Special 2006 - December 2006 Interview with Deborah Rathjen, CEO, Bionomics Deborah Rathjen, CEO, talks to Fintan Walton about the Australian company Bionomics. She gives a brief account of the history of Bionomics and how it has grown from a virtual company to a fully developed biotech operation. Deborah provides an overview of Bionomics' product portfolio and outlines the rationale behind the company's two business acquisitions. They discuss the challenges of integrating and managing a multisite global operation as well as Bionomics' ongoing out-licensing business strategy. http://www.pharmaventuresbusinessreview.com/media/pvbr_f2f14_rathjen.m4v Fri, 15 Dec 2006 12:00:00 -0000 Business no 18:55 fintan, walton, Deborah Rathjen, CEO, Bionomics, adelaide, biotechnology, AusBiotech, Australia, pharmaceutical, television, business, deals, licensing, mergers, financing, initial public offering, ipo, acquisitions, pharmadeals, valuation, review PharmaVentures Ltd Australia Biotech Special 2006 - December 2006 Interview with Brigitte Smith, Partner, GBS Venture Partners Brigitte Smith talks to Fintan Walton about the story of the Australian company GBS Ventures and its creation following a management buyout from Rothschild Bioscience Managers. They reflect on the company's investment strategy as the biotech sector has matured and discuss a recent government seed capital fund that GBS has been involved in. Brigitte outlines the reasoning behind some of the company's recent investments and the importance of effective communication between biotech companies and investors, and also provides advice on when to go public. http://www.pharmaventuresbusinessreview.com/media/pvbr_f2f13a_smith.m4v Fri, 15 Dec 2006 12:00:00 -0000 Business no 20:40 fintan, walton, Brigitte Smith, Partner, GBS Venture Partners, Melbourne, biotechnology, AusBiotech, Australia, pharmaceutical, television, licensing, mergers, financing, initial public offering, ipo, acquisitions, pharmadeals, valuation, review PharmaVentures Ltd Australia Biotech Special 2006 - December 2006 Interview with Sue MacLeman, CEO, Benitec Sue MacLeman talks to Fintan Walton about the story of the Australian company Benitec, its technologies and the role she has played within the company since she joined it in September 2006. They discuss the resolution of patent issues and how the company.s business model has moved from one focused on litigation to one on collaboration. Sue talks about Benitec's ongoing strategic plan and the importance of its long-term licensing relationships. She also reflects on recent company acquisitions in the RNAi sectors and what this might mean for the future of Benitec. http://www.pharmaventuresbusinessreview.com/media/pvbr_f2f16_macleman.m4v Fri, 15 Dec 2006 12:00:00 -0000 Business no 20:40 fintan, walton, Sue MacLeman, CEO, Benitec, Melbourne, biotechnology, AusBiotech, Australia, pharmaceutical, television, business, deals, licensing, mergers, financing, initial public offering, ipo, acquisitions, pharmadeals, valuation, review PharmaVentures Ltd Australia Biotech Special 2006 - December 2006 Interview with Stephen Porges, CEO, Proteome Systems Stephen Porges talks to Fintan Walton about the history and science behind Proteome Systems. He discusses the company's move away from being technology based towards becoming a pipeline company. They review the company's business model and its intention to seek product development partners. Stephen also touches on capital restructuring and the problems associated with being a listed company on the ASX. http://www.pharmaventuresbusinessreview.com/media/pvbr_f2f15_porges.m4v Fri, 15 Dec 2006 12:00:00 -0000 Business no 20:13 fintan, walton, Sue MacLeman, CEO, Benitec, Melbourne, biotechnology, AusBiotech, Australia, pharmaceutical, television, business, deals, licensing, mergers, financing, initial public offering, ipo, acquisitions, pharmadeals, valuation, review PharmaVentures Ltd Australia Biotech Special 2006 - December 2006 Interviews with Alison Coutts and Rocco Iannello Fintan Walton hosts this special edition of 'Meet the Experts', in which Alison Coutts and Rocco Iannello reflect on the Australian biotech scene at the end of 2006. Alison reviews the current situation in the Australian financial markets and highlights the importance for small biotech companies of effectively managing expectations. Rocco appraises the health of the Australian University technology transfer and IP situation, and outlines the need for novel funding methods to commercialise new innovation. Together they discuss the number of small-cap companies on the ASX and the increasing sophistication of the biotech capital markets in Australia. http://www.pharmaventuresbusinessreview.com/media/pvbr_f2f11_coutts_rocco.m4v Fri, 15 Dec 2006 12:00:00 -0000 Business no 20:49 fintan, walton, Alison Coutts, Rocco Iannello, Sydney, Melbourne, biotechnology, AusBiotech, Australia, pharmaceutical, television, business, deals, licensing, mergers, financing, initial public offering, ipo, acquisitions, pharmadeals, valuation, review PharmaVentures Ltd Special Interview with Alice Huxley, Speedel Interview with Alice Huxley, Speedel Dr Alice Huxley talks to Fintan Walton about setting up Speedel and her motivations for doing so, following the merger of Ciba-Geigy and Sandoz in 1996 to create Novartis. They discuss the company's drug development programmes and how its lead compound is nearing launch. Dr Huxley also reviews the company's business strategy and the important balance between collaborative R and D and in-house development. Finally she outlines the reasoning behind the decision to float Speedel on the Swiss stock exchange and discusses what the future might hold for the small biotechnology company. http://www.pharmaventuresbusinessreview.com/media/pvbr_f2f11_alice.m4v Mon, 11 Dec 2006 12:00:00 -0000 Business no 20:40 fintan, walton, Alice Huxley, biotechnology, Speedel, Novartis, Switzerland, pharmaceutical, television, business, deals, licensing, mergers, financing, initial public offering, ipo, acquisitions, pharmadeals, valuation, review PharmaVentures Ltd Special Interview with Matt Gardner, BayBio Interview with Matt Gardner, BayBio To coincide with the launch of the 2007 BayBio:IMPACT report, Matthew Gardner, President of BayBio, Northern California's Life Science Trade Association, talks to Fintan Walton about the role that BayBio plays in serving the life sciences industry in the Bay area of Northern California - the birthplace of the biotech industry. BayBio has 300 member companies, and Matthew outlines the features of this community that have contributed to its successful development. With approximately 370 products in Phase II and III development, and many new products coming to market, the biotech companies in the region are entering an exciting and challenging era in which, after 30 years of research, they are hoping to capitalise on their past success. http://www.pharmaventuresbusinessreview.com/media/pvbr_f2f4_gardener.m4v Sun, 26 Nov 2006 12:00:00 -0000 Business no 21:48 fintan, walton, Matt Gardner, biotechnology, Baybio, biotech, California, pharmaceutical, television, business, deals, licensing, mergers, financing, initial public offering, ipo, acquisitions, pharmadeals, valuation, review PharmaVentures Ltd Special Interview with Rob Hockney, AstraZeneca Interview with Rob Hockney, AstraZeneca Robert Hockney talks to Fintan Walton about alliance management at AstraZeneca http://www.pharmaventuresbusinessreview.com/media/pvbr_f2f10_hockney.m4v Sun, 26 Nov 2006 12:00:00 -0000 Business no 21:24 fintan, walton, Robert Hockney, biotechnology, Cambridge Antibody Technology, biotech, AstraZeneca, CAT, pharmaceutical, television, business, deals, licensing, mergers, financing, initial public offering, ipo, acquisitions, pharmadeals, valuation, review PharmaVentures Ltd Special Edition of PharmaVentures Business Review Interview with Zogenix Stephen Farr and Jonathan Rigby, two members of Zogenix's founding team, talk to Fintan Walton about setting up the company and the novel, needle-free injection technology platform on which it is based. They discuss Zogenix's business model for becoming a speciality pharmaceutical company and outline their plan to drive their lead product to an NDA filing. Stephen and Jonathan provide an overview of the Intraject® technology and of the company's plan to form strategic partnerships in order to produce novel products and add value to existing therapies. Zogenix's plan to develop its own specialist sales force for the US market as well as its intention to seek a co-promotion partner for entrance into Europe are also covered. http://www.pharmaventuresbusinessreview.com/media/pvbr_f2f5_farr_rigby.m4v Mon, 20 Nov 2006 12:00:00 -0000 Business no 20:53 fintan, walton, Stephen Farr, Jonathan Rigby, Zogenix, biotechnology, speciality, biotech, Intrajet, pharmaceutical, television, business, deals, licensing, mergers, financing, initial public offering, ipo, acquisitions, pharmadeals, valuation, review PharmaVentures Ltd The Seventh Edition of PharmaVentures Business Review World's first pharmaceutical business show PharmaVentures Business Review is a new cutting edge television business show that provides viewers with effortless access to essential industry intelligence. As the first of its kind it is already watched by thousands throughout the pharma and biotech industry, as well as the financial sector. PharmaVentures Business Review will keep you informed with our insightful coverage of major transactions and industry trends, as well as giving you exclusive access to topical interviews with senior executives and independent expert opinions. The programme is presented by Fintan Walton, CEO of PharmaVentures and Ann Salter and comprises four distinct sections: The Month in Review - The essential details of key business transactions selected by PharmaVentures' team of experienced business analysts. The Business Report - An analysis of important industry trends in deal making, therapies and technology area. Face-to-Face - In-depth interviews providing you with an insight into the real-life workings of the deal making process. Meet the Experts - Round-table discussions giving you access to the experience of leading analysts, commentators and decision makers from various sectors of the industry worldwide. http://www.pharmaventuresbusinessreview.com/media/pvbr_ep7_full.m4v Sat, 11 Nov 2006 12:00:00 -0000 Business no 42:28 biotechnology, biotech, pharmaceutical, television, business, deals, licensing, mergers, financing, initial public offering, ipo, acquisitions, commentary, pharmadeals, valuation, review PharmaVentures Ltd Interview with Simon Moroney, CEO, MorophoSys Interview with Simon Moroney, CEO, MorophoSys Simon Moroney, CEO, MorophoSys talks to Fintan Walton about MorphoSys's founding in the early days of biotech in Germany and its focus on monoclonal antibodies. They discuss how MorphoSys grew despite the difficulties of financing in Germany and the sceptical view of monoclonal antibodies by pharmaceutical companies in the early days. Dr Moroney discusses in depth their relationship with Roche and the development of their Alliance Management Team. He, also, talks about the the financial performance of MorphoSys, its recent acquisitions and the future strategy of his company going forward. http://www.pharmaventuresbusinessreview.com/media/pvbr_f2f6_moroney.m4v Sat, 11 Nov 2006 11:00:00 -0000 Business no 20:24 Simon Moroney, MorphoSys, monoclonal, antibodies, Roche, Centocor, biotech, pharmaceutical, business, deals, licensing, mergers, financing, initial public offering, ipo, acquisitions, pharmadeals, valuation, review PharmaVentures Ltd An interview with Eric de La Fortelle An interview with Eric de La Fortelle Fintan Walton talks to Eric de La Fortelle, Global Head, External Research and Technology, F. Hoffmann-La Roche, about his role within the Pharma Partnering Group at Roche. Eric outlines the structure of the Pharma Partnering Group and Roche's overall model for alliance management. The discussion covers Roche's long-term alliance with MorphoSys and the integrated approach that has allowed the companies to harness both science and business, and develop and maintain a successful alliance. Eric also highlights the importance of flexibility in management strategy when assessing alliance candidates and gives an overview of what Roche looks for in a potential partner. http://www.pharmaventuresbusinessreview.com/media/pvbr_ep7_3.m4v Mon, 13 Nov 2006 00:00:00 -0000 Business no 22:04 Eric de La Fortelle, Roche, Fortelle, F.Hoffmann, Pharma Partnering Group, alliance management, MorphoSys, management strategy PharmaVentures Ltd Special Edition of PharmaVentures Business Review Interview with Peter Cook, Biota Peter Cook talks to Fintan Walton about Biota's ongoing business strategy and drug development programmes. Mr Cook discusses the various challenges that biotech companies must face in order to remain successful, including the necessity to balance diversification and specialisation, and the risks and rewards of raising capital in overseas markets. They also talk about Biota's success with Relenza™ and the ongoing management of its relationship with GlaxoSmithKline, as well the licensing of Biota's lead RSV compound to MedImmune. http://www.pharmaventuresbusinessreview.com/media/pvbr_f2f8_cook.m4v Mon, 06 Nov 2006 12:00:00 -0000 Business no 20:55 fintan, walton, Australia, Biota, Relenza, GSK, Glaxo, biotechnology, biotech, pharmaceutical, television, business, deals, licensing, mergers, financing, initial public offering, ipo, acquisitions, commentary, pharmadeals, valuation, review PharmaVentures Ltd Interview with Richard de Souza, Archimedes Pharma Interview with Richard de Souza, Archimedes Pharma Richard de Souza talks to Fintan Walton about Archimedes Pharma's unique business and funding model. Mr de Souza gives an insight into how the company's experienced management team was put in place and its proposed time-scales for becoming cash positive. Other aspects of Archimedes' business strategy are also discussed, including the company's aim to effect business acquisitions in the five major European markets http://www.pharmaventuresbusinessreview.com/media/pvbr_f2f3_de_souza.m4v Mon, 30 Oct 2006 12:00:00 -0000 Business no 20:55 fintan, walton, de souza, Archimedes, Warburg Pincus, biotechnology, biotech, pharmaceutical, television, business, deals, licensing, mergers, financing, initial public offering, ipo, acquisitions, commentary, pharmadeals, valuation, review PharmaVentures Ltd Interview with Dr Mark Ashton, Evotec Interview with Dr Mark Ashton, Evotec Dr Mark Ashton talks to Fintan Walton about Evotec's evolving business model, which is based on both contract research services and proprietary research in the CNS field. In particular, they discuss Evotec's successful alliance history with Roche that dates back to 2001. Dr Ashton talks in depth about the terms of these risk-sharing agreements and how they are managed. He also offers an insight into Evotec's future strategic plans. http://www.pharmaventuresbusinessreview.com/media/pvbr_f2f2_ashton.m4v Mon, 16 Oct 2006 12:00:00 -0000 Business no 20:55 fintan, walton, Ashton, Evotec, Roche, biotechnology, biotech, pharmaceutical, television, business, deals, licensing, mergers, financing, initial public offering, ipo, acquisitions, commentary, pharmadeals, valuation, review PharmaVentures Ltd Interview with Dr H Ming Pang, Simcere Pharmaceuticals Interview with Dr H Ming Pang, Simcere Pharmaceuticals Dr Pang talks to Fintan Walton about biotechnology trends in China. He examines what the Chinese pharmaceutical and biotechnology industry has to offer the global market, discusses the opportunities in China and presents his thoughts on the challenges that this region faces. The discussion provides an in-depth analysis and informative overview of this emergent territory, which has lately been the subject of much attention. http://www.pharmaventuresbusinessreview.com/media/pvbr_f2f7_pang.m4v Mon, 09 Oct 2006 12:00:00 -0000 Business no 22:35 fintan, walton, Ming Pang, Simcere Pharmaceuticals, biotechnology, biotech, pharmaceutical, television, business, deals, licensing, mergers, financing, initial public offering, ipo, acquisitions, commentary, pharmadeals, valuation, review PharmaVentures Ltd The Sixth Edition of PharmaVentures Business Review World's first pharmaceutical business show PharmaVentures Business Review is a new cutting edge television business show that provides viewers with effortless access to essential industry intelligence. As the first of its kind it is already watched by thousands throughout the pharma and biotech industry, as well as the financial sector. PharmaVentures Business Review will keep you informed with our insightful coverage of major transactions and industry trends, as well as giving you exclusive access to topical interviews with senior executives and independent expert opinions. The programme is presented by Fintan Walton, CEO of PharmaVentures and comprises four distinct sections: The Month in Review - The essential details of key business transactions selected by PharmaVentures' team of experienced business analysts. The Business Report - An analysis of important industry trends in deal making, therapies and technology area. Face-to-Face - In-depth interviews providing you with an insight into the real-life workings of the deal making process. Meet the Experts - Round-table discussions giving you access to the experience of leading analysts, commentators and decision makers from various sectors of the industry worldwide. http://www.pharmaventuresbusinessreview.com/media/pvbr_ep6_full.m4v Mon, 09 Oct 2006 12:00:00 -0000 Business no 40:20 biotechnology, biotech, pharmaceutical, television, business, deals, licensing, mergers, financing, initial public offering, ipo, acquisitions, commentary, pharmadeals, valuation, review PharmaVentures Ltd Special Edition of PharmaVentures Business Review Interview with Onno van de Stolpe, CEO, Galapagos Onno van de Stolpe talks to Fintan Walton, about Galapagos' current business model and overall strategic outlook. They discuss the integration of BioFocus following its acquisition by Galapagos in November 2005, as well as the more recent acquisition of the drug discovery service division of Discovery Partners International. Onno talks in detail about managing Galapagos' strategic osteoarthritis alliance with GlaxoSmithKline and the challenges the company now faces as it expands its operations across the globe. http://www.pharmaventuresbusinessreview.com/media/pvbr_ep4_f2f_1.m4v Mon, 02 Oct 2006 12:00:00 -0000 Business no 17:01 fintan, walton, van de Stolpe, Galapagos, biotechnology, biotech, pharmaceutical, television, business, deals, licensing, mergers, financing, initial public offering, ipo, acquisitions, commentary, pharmadeals, valuation, review PharmaVentures Ltd The Fifth Edition of PharmaVentures Business Review World's first pharmaceutical business show PharmaVentures Business Review is a new cutting edge television business show that provides viewers with effortless access to essential industry intelligence. As the first of its kind it is already watched by thousands throughout the pharma and biotech industry, as well as the financial sector. PharmaVentures Business Review will keep you informed with our insightful coverage of major transactions and industry trends, as well as giving you exclusive access to topical interviews with senior executives and independent expert opinions. The programme is presented by Fintan Walton, CEO of PharmaVentures and comprises four distinct sections: The Month in Review - The essential details of key business transactions selected by PharmaVentures' team of experienced business analysts. The Business Report - An analysis of important industry trends in deal making, therapies and technology area. Face-to-Face - In-depth interviews providing you with an insight into the real-life workings of the deal making process. Meet the Experts - Round-table discussions giving you access to the experience of leading analysts, commentators and decision makers from various sectors of the industry worldwide. http://www.pharmaventuresbusinessreview.com/media/pvbr_ep5_full.m4v Mon, 11 Sep 2006 12:00:00 -0000 Business no 36:20 biotechnology, biotech, pharmaceutical, television, business, deals, licensing, mergers, financing, initial public offering, ipo, acquisitions, commentary, pharmadeals, valuation, review PharmaVentures Ltd Special Edition of PharmaVentures Business Review - September 2006 Background to the world's first pharmaceutical business show Ann Salter interviews Fintan Walton the creator of PharmaVentures Business Review to find out why he launched the world's first business show for the pharmaceutical industry. http://idisk.mac.com/fintanwalton/Public/interviewfintan.m4v Mon, 04 Sep 2006 12:00:00 -0000 Business no 9:56 fintan, walton, biotechnology, biotech, pharmaceutical, television, business, deals, licensing, mergers, financing, initial public offering, ipo, acquisitions, commentary, pharmadeals, valuation, review PharmaVentures Ltd The Fourth Edition of PharmaVentures Business Review World's first pharmaceutical business show PharmaVentures Business Review is a new cutting edge television business show that provides viewers with effortless access to essential industry intelligence. As the first of its kind it is already watched by thousands throughout the pharma and biotech industry, as well as the financial sector. PharmaVentures Business Review will keep you informed with our insightful coverage of major transactions and industry trends, as well as giving you exclusive access to topical interviews with senior executives and independent expert opinions. The programme is presented by Fintan Walton, CEO of PharmaVentures and comprises four distinct sections: The Month in Review - The essential details of key business transactions selected by PharmaVentures' team of experienced business analysts. The Business Report - An analysis of important industry trends in deal making, therapies and technology area. Face-to-Face - In-depth interviews providing you with an insight into the real-life workings of the deal making process. Meet the Experts - Round-table discussions giving you access to the experience of leading analysts, commentators and decision makers from various sectors of the industry worldwide. http://www.pharmaventuresbusinessreview.com/media/pvbr_ep4_full.m4v Tue, 15 Aug 2006 12:00:00 -0000 Business no 36:20 biotechnology, biotech, pharmaceutical, television, business, deals, licensing, mergers, financing, initial public offering, ipo, acquisitions, commentary, pharmadeals, valuation, review PharmaVentures Ltd Interview with Bruce Carter Interview with Bruce Carter Fintan Walton, CEO of PharmaVentures, talks exclusively to Bruce Carter, President and CEO of ZymoGenetics, a company that celebrated its 25th anniversary on 22 June 2006. Bruce discusses a number of aspects of ZymoGenetics' operations, including its relationship with previous owners Novo Nordisk, its alliance with Serono and its drug development model. Bruce also shares his views and advice on biotech acquisitions and the key characteristics of a successful biotech CEO. http://www.pharmatelevision.com/media/pvbr_ep3_3.m4v Thu, 13 Jul 2006 00:00:00 -0000 Business no 18:11 biotechnology, biotech, pharmaceutical, television, business, deals, licensing, mergers, financing, initial public offering, ipo, acquisitions, commentary, pharmadeals, review PharmaVentures Ltd The Third Edition of PharmaVentures Business Review World's first pharmaceutical business show PharmaVentures Business Review is a new cutting edge television business show that provides viewers with effortless access to essential industry intelligence. As the first of its kind it is already watched by thousands throughout the pharma and biotech industry, as well as the financial sector. PharmaVentures Business Review will keep you informed with our insightful coverage of major transactions and industry trends, as well as giving you exclusive access to topical interviews with senior executives and independent expert opinions. The programme is presented by Fintan Walton, CEO of PharmaVentures and comprises four distinct sections: The Month in Review - The essential details of key business transactions selected by PharmaVentures' team of experienced business analysts. The Business Report - An analysis of important industry trends in deal making, therapies and technology area. Face-to-Face - In-depth interviews providing you with an insight into the real-life workings of the deal making process. Meet the Experts - Round-table discussions giving you access to the experience of leading analysts, commentators and decision makers from various sectors of the industry worldwide. http://www.pharmaventuresbusinessreview.com/media/pvbr_ep3_full.m4v Mon, 10 Jul 2006 12:00:00 -0000 Business no 31:24 biotechnology, biotech, pharmaceutical, television, business, deals, licensing, mergers, financing, initial public offering, ipo, acquisitions, commentary, pharmadeals, review PharmaVentures Ltd The Second Edition of PharmaVentures Business Review World's first pharmaceutical business show PharmaVentures Business Review is a new cutting edge television business show that provides viewers with effortless access to essential industry intelligence. As the first of its kind it is already watched by thousands throughout the pharma and biotech industry, as well as the financial sector. PharmaVentures Business Review will keep you informed with our insightful coverage of major transactions and industry trends, as well as giving you exclusive access to topical interviews with senior executives and independent expert opinions. The programme is presented by Fintan Walton, CEO of PharmaVentures and comprises four distinct sections: The Month in Review - The essential details of key business transactions selected by PharmaVentures' team of experienced business analysts. The Business Report - An analysis of important industry trends in deal making, therapies and technology area. Face-to-Face - In-depth interviews providing you with an insight into the real-life workings of the deal making process. Meet the Experts - Round-table discussions giving you access to the experience of leading analysts, commentators and decision makers from various sectors of the industry worldwide. http://www.pharmaventuresbusinessreview.com/media/pvbr_ep2_full.m4v Fri, 16 Jun 2006 12:00:00 -0000 Business no 30:00 biotechnology, biotech, pharmaceutical, television, business, deals, licensing, mergers, financing, initial public offering, ipo, acquisitions, commentary, pharmadeals, review PharmaVentures Ltd The First Edition of PharmaVentures Business Review World's first pharmaceutical business show PharmaVentures Business Review is a new cutting edge television business show that provides viewers with effortless access to essential industry intelligence. As the first of its kind we expect this show to be watched by thousands throughout the pharma and biotech industry, as well as the financial sector. PharmaVentures Business Review will keep you informed with our insightful coverage of major transactions and industry trends, as well as giving you exclusive access to topical interviews with senior executives and independent expert opinions. The programme is presented by Fintan Walton, CEO of PharmaVentures and comprises four distinct sections: The Month in Review - The essential details of key business transactions selected by PharmaVentures' team of experienced business analysts. The Business Report - An analysis of important industry trends in deal making, therapies and technology area. Face-to-Face - In-depth interviews providing you with an insight into the real-life workings of the deal making process. Meet the Experts - Round-table discussions giving you access to the experience of leading analysts, commentators and decision makers from various sectors of the industry worldwide. http://www.pharmaventuresbusinessreview.com/media/pvbr-pilot.m4v Wed, 17 May 2006 12:00:00 -0000 Business no 45:24 australia, biotechnology, biotech, pharmaceutical, television, business, deals, licensing, mergers, acquisitions, commentary, pharmadeals, review